4 Acute hepatitis C

Biomedical Research Reports

Volumn 2, Issue C, 2000, Pages 71-83

  Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002727348     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(00)80008-3     Document Type: Article

References (58)

1. Alter M.J., Gallagher M., Morris T.T., et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 336 (1997) 741-746
2. Center for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47 No. RR-19 (1998) 1-39
3. Donahue J.G., Munoz A., Ness R.M., et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327 (1992) 369-373
4. Alter M.J., Hadler S.C., Judson F.N., et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 264 (1990) 2231-2235
5. [abstract]. Williams I.T., Sabin K., Fleenor M., et al. Current patterns of hepatitis C virus transmission in the United States: the role of drugs and sex. Hepatology 28 (1998) 497A
6. Alter H.J. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med 115 (1991) 644-649
7. Alter M.J., Margolis H.S., Krawczynski J., et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327 (1992) 1899-1905
8. Hoofnagle J.H., and Hepatitis C. The clinical spectrum of disease. Hepatology 26 Suppl 1 (1997) 15S-20S
9. Lee W. Acute liver failure. N Engl J Med 329 (1993) 1862-1872
10. Alter H.J., Purcell R.H., Shih J.W., et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321 (1989) 1494-1500
11. Estaban J.I., Gonzalez A., Hernandez J.M., et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion associated hepatitis. N Engl J Med 323 (1990) 1107-1112
12. Aach R.D., Stevens C.E., Hollinger F.B., et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 325 (1991) 1325-1329
13. Tremolada F., Casarin C., Tagger A., et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 114 (1991) 227-281
14. Tassopoulos N.C., Hatzakis A., Delladetsima I., Koutelou M.G., Todoulos A., and Miriagou V. Role of hepatitis C virus in acute non-A, non-B hepatitis in Greece: a 5-year prospective study. Gastroenterology 102 (1992) 969-972
15. Hino K., Sainokami S., Shimoda K., Niwa H., and Iino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 39 (1994) 19-27
16. Barrera J.M., Bruguera M., Ercilla M.G., et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21 (1995) 639-644
17. Farci P., Alter H.J., Wong D., et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325 (1991) 98-104
18. Alter J.H., Sanchez-Pescador R., Urdea M.S., et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatitis 2 (1995) 121-132
19. Kenny-Walsh E., and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340 (1999) 1228-1233
20. Seeff L.B., Buskell-Bales Z., Wright E.C., et al. National Heart, Lung and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327 (1992) 1906-1911
21. Vogt M., Lang T., Frösner G., et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341 (1999) 866-870
22. Rehermann B., Change K.M., McHutchison J., et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70 (1996) 7092-7102
23. Shakil O., Conry-Cantilena C., Alter H.J., et al. Volunteer blood donors with antibodies to hepatitis C virus: clinical, biochemical, virological and histological features. Ann Intern Med 123 (1995) 330-337
24. Villano S.A., Vlahov D., Nelson K.E., Cohn S., and Thomas D.L. Persistence of viremia and the importance of long-term follow-up after hepatitis C infection. Hepatology 29 (1999) 908-914
25. Alberti A., Morsica G., Chemello L., et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340 (1992) 697-698
26. Lau D., Kleiner D.E., Ghany M.G., Park Y., Schmid P., and Hoofnagle J.H. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28 (1998) 1121-1127
27. Gretch D. Diagnostic tests for hepatitis C. Hepatology 26 Suppl 1 (1997) 43S-47S
28. Sheen I.S., Liaw T.F., Lin D.Y., and Chu C.M. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol 24 (1996) 525-531
29. Chau K.H., Dawson G.J., Mushahwar I.K., et al. IgM antibody response to hepatitis C virus antigens in acute and chronic post-transfusion non-A, non-B hepatitis. J Virol Methods 35 (1991) 343-352
30. Yuki N., Hayashi N., Ohkawa K., et al. The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 22 (1995) 402-406
31. Quiroga J.A., Binsbergen J.V., Wang C.Y., et al. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome. Hepatology 22 (1995) 1635-1640
32. Fournillier-Jacob A., Lunel F., Cahour A., et al. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C. J Med Virol 50 (1996) 159-167
33. Omata M., Yokosuka O., Takano S., et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338 (1991) 914-915
34. Viladomiu L., Genescà J., Esteban J.I., et al. Interferon-α in acute posttransfusion hepatitis C: a randomized controlled trial. Hepatology 15 (1992) 767-769
35. (Suppl). Tassopoulos N.C., Koutelou M.G., Papatheodoridis G., et al. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut 34 (1993) S130-S132
36. Alberti A., Chemello L., Belussi F., et al. Outcome of acute hepatitis C and role of interferon alpha therapy. In: Nishioka K., Suzuki H., and Oda T. (Eds). Viral hepatitis and liver disease (1994), Springer-Verlag, Tokyo 604-606
37. Palmovic D.I., Kurelac I., and Crnjakovic-Palmovic J. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha. Infection 22 (1994) 222-223
38. Lampertico P., Rumi M., Romeo R., et al. A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 19 (1994) 19-22
39. Hwang S.-J., Lee S.-D., Chang C.-Y., Lu R.-H., and Lo K.-J. A randomized controlled trial of recombinant interferon alfa 2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 21 (1994) 831-836
40. Takano S., Satomura Y., Omata M., and Japan Acute Hepatitis Cooperative Study Group. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 107 (1994) 805-811
41. Calleri G., Colombatto P., Gozzelino M., et al. Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 30 (1998) 181-184
42. Cammá C., Almasio P., and Craxí A. Interferon as treatment for acute hepatitis C: a meta-analysis. Dig Dis Sci 41 (1996) 1248-1255
43. Vogel W., Graziadei I., Umlauft F., et al. High dose interferon-alfa 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 41 (1996) 81S-85S
44. Ohnishi K., Nomura F., and Iida S. Treatment of posttransfusion non-A, non-B hepatitis acute and chronic hepatitis with human fibroblast -interferon: a preliminary report. Am J Gastroenterol 84 (1989) 596-600
45. Christie J.M., Healey C.J., Watson J., et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: a 2-year follow up. Clin Exp Immunol 110 (1997) 4-8
46. Süleymanlar I., Sezer T., Işitan F., Yakupoǧlu G., and Süleymanlar G. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron 79 (1998) 353-354
47. Kiyosawa K., Sodeyama T., Tanaku E., et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 115 (1991) 367-369
48. Arai Y., Noda K., Enomoto V., et al. A prospective study of hepatitis C virus infection after needlestick accidents. Liver 16 (1996) 331-334
49. Nakano Y., Kiyosawa K., Sodeyama T., et al. Acute hepatitis C transmitted by needlestick accident despite short duration interferon treatment. J Gastroenterol Hepatol 10 (1995) 609-611
50. Poignet J.-L., Dego F., Bouchardeau F., Chauveau P., and Courouce A.M. Complete response to interferon-alpha for acute hepatitis C after needlestick injury in a hemodialysis nurse. J Hepatol 23 (1995) 740-741
51. Noguchi S., Sata M., Suzuki H., Ohba K., Mizokami M., and Tanikawa K. Early therapy with interferon for acute hepatitis C acquired through a needlestick. Clin Infect Dis 24 (1997) 992-994
52. Yang S.S., Wu C.H., Huang C.S., et al. Early interferon therapy and abortion of posttransfusion hepatitis C viral infection. J Clin Gastroenterol 21 (1995) 38-41
53. Sata M., Ide T., Noguchi S., et al. Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick. J Hepatol 27 (1997) 425-426
54. Davis G.L., and Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26 Suppl 1 (1997) 112S-127S
55. Nousbaum J.-B., Pol S., Nalpas B., et al. Hepatitis C virus type 1b infection in France and Italy. Ann Intern Med 122 (1995) 161-168
56. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
57. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
58. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499